Fmoc-Ala-OHCAS# 35661-39-3 |
- PF-4708671
Catalog No.:BCC5031
CAS No.:1255517-76-0
- BIX 02565
Catalog No.:BCC4303
CAS No.:1311367-27-7
- BI-D1870
Catalog No.:BCC5030
CAS No.:501437-28-1
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 35661-39-3 | SDF | Download SDF |
| PubChem ID | 100108 | Appearance | Powder |
| Formula | C18H17NO4 | M.Wt | 311.3 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in water or 1% acetic acid | ||
| Chemical Name | 2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid | ||
| SMILES | CC(C(=O)O)NC(=O)OCC1C2=CC=CC=C2C3=CC=CC=C13 | ||
| Standard InChIKey | QWXZOFZKSQXPDC-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H17NO4/c1-11(17(20)21)19-18(22)23-10-16-14-8-4-2-6-12(14)13-7-3-5-9-15(13)16/h2-9,11,16H,10H2,1H3,(H,19,22)(H,20,21) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Fmoc-Ala-OH Dilution Calculator
Fmoc-Ala-OH Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 3.2123 mL | 16.0617 mL | 32.1234 mL | 64.2467 mL | 80.3084 mL |
| 5 mM | 0.6425 mL | 3.2123 mL | 6.4247 mL | 12.8493 mL | 16.0617 mL |
| 10 mM | 0.3212 mL | 1.6062 mL | 3.2123 mL | 6.4247 mL | 8.0308 mL |
| 50 mM | 0.0642 mL | 0.3212 mL | 0.6425 mL | 1.2849 mL | 1.6062 mL |
| 100 mM | 0.0321 mL | 0.1606 mL | 0.3212 mL | 0.6425 mL | 0.8031 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Fmoc-Ala-OH
- SB525334
Catalog No.:BCC2531
CAS No.:356559-20-1
- SB-505124 hydrochloride
Catalog No.:BCC1930
CAS No.:356559-13-2
- NSC 3852
Catalog No.:BCC2423
CAS No.:3565-26-2
- Benzbromarone
Catalog No.:BCC4634
CAS No.:3562-84-3
- Mesuaxanthone A
Catalog No.:BCN5298
CAS No.:3561-81-7
- CP 20961
Catalog No.:BCC6063
CAS No.:35607-20-6
- N-Desethyl Sunitinib
Catalog No.:BCC1792
CAS No.:356068-97-8
- Toceranib
Catalog No.:BCC2005
CAS No.:356068-94-5
- Darapladib
Catalog No.:BCC1515
CAS No.:356057-34-6
- Fluocinonide
Catalog No.:BCC4953
CAS No.:356-12-7
- Betmidin
Catalog No.:BCN8253
CAS No.:35589-22-1
- tert-Butyl rosuvastatin
Catalog No.:BCC9163
CAS No.:355806-00-7
- Fmoc-Phe-OH
Catalog No.:BCC3535
CAS No.:35661-40-6
- Fmoc-Leu-OH
Catalog No.:BCC3509
CAS No.:35661-60-0
- Deoxylapachol
Catalog No.:BCN5299
CAS No.:3568-90-9
- Dihydrobaicalein
Catalog No.:BCN3887
CAS No.:35683-17-1
- Questinol
Catalog No.:BCN7443
CAS No.:35688-09-6
- Valerenic acid
Catalog No.:BCC7546
CAS No.:3569-10-6
- Naloxone HCl
Catalog No.:BCC4612
CAS No.:357-08-4
- Brucine
Catalog No.:BCN2390
CAS No.:357-57-3
- Galantamine
Catalog No.:BCN2868
CAS No.:357-70-0
- Albaspidin AA
Catalog No.:BCN5300
CAS No.:3570-40-9
- Moslosooflavone
Catalog No.:BCN5301
CAS No.:3570-62-5
- Pemetrexed disodium hemipenta hydrate
Catalog No.:BCC1844
CAS No.:357166-30-4
Friendly strategy to prepare encoded one bead-one compound cyclic peptide library.[Pubmed:23971518]
ACS Comb Sci. 2013 Oct 14;15(10):525-9.
One bead-one peptide libraries allow the screening of suitable ligands for any target protein. Short cyclic peptides are ideal ligands for affinity chromatography because of their high affinity and selectivity for the target protein and stability against proteases. We designed a library synthesis strategy to facilitate the identification of cyclic peptides by MS consisting of (a) sequential incorporation of a mixture of Fmoc-Ala-OH and Fmoc-Asp[2-phenylisopropyl (OPp)]-OH (15:85) to Gly-oxymethylbenzamide-ChemMatrix (Gly-HMBA-CM) resin, (b) synthesis of the combinatorial library on the resin by the divide-couple-recombine method, (c) removal of OPp with 4% TFA, (d) peptide cyclization on solid phase through side-chain Asp and amino terminus, and (e) removal of side chain protecting groups with a 95% TFA cocktail. Peptides were cleaved from the beads with ammonia and the linear code was sequenced by MALDI-TOF MS/MS. The high capacity of ChemMatrix resin together with the sensitivity of MS allows code sequencing from a single bead.
Identification of Fmoc-beta-Ala-OH and Fmoc-beta-Ala-amino acid-OH as new impurities in Fmoc-protected amino acid derivatives.[Pubmed:15686539]
J Pept Res. 2005 Jan;65(1):90-7.
During the manufacture of a proprietary peptide drug substance a new impurity appeared unexpectedly. Investigation of its chemical structure established the impurity as a beta-Ala insertion mutant of the mother peptide. The source of the beta-Ala was identified as contamination of the Fmoc-Ala-OH raw material with Fmoc-beta-Ala-Ala-OH. Further studies also demonstrated the presence of beta-Ala in other Fmoc-amino acids, particularly in Fmoc-Arg(Pbf)-OH. In this case, it was due to the presence of both Fmoc-beta-Ala-OH and Fmoc-beta-Ala-Arg(Pbf)-OH. It is concluded that beta-Ala contamination of Fmoc-amino acid derivatives is a general and hitherto unrecognized problem to suppliers of Fmoc-amino acid derivatives. The beta-Ala is often present as Fmoc-beta-Ala-OH and/or as a dipeptide, Fmoc-beta-Ala-amino acid-OH. In collaboration with the suppliers, new specifications were introduced, recognizing the presence of beta-Ala-related impurities in the raw materials and limiting them to acceptable levels. The implementation of these measures has essentially eliminated beta-Ala contamination as a problem in the manufacture of the drug substance.
